Extensively Drug-Resistant Tuberculosis

Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC.

Also Known As:

Extremely Drug-Resistant Tuberculosis; Tuberculosis, Extremely Drug-Resistant; XDR-TB; Drug-Resistant Tuberculoses, Extensively; Drug-Resistant Tuberculoses, Extremely; Drug-Resistant Tuberculosis, Extensively; Drug-Resistant Tuberculosis, Extremely; Extensively Drug Resistant Tuberculosis; Extensively Drug-Resistant Tuberculoses; Extremely Drug Resistant Tuberculosis; Extremely Drug-Resistant Tuberculoses; Tuberculoses, Extensively Drug-Resistant; Tuberculoses, Extremely Drug-Resistant; Tuberculosis, Extensively Drug Resistant; Tuberculosis, Extremely Drug Resistant; Tuberculosis, Extensively Drug-Resistant

Infections: 526564
- Bacterial Infections and Mycoses: 1
  - Bacterial Infections: 24368
    - Gram-Positive Bacterial Infections: 348
      - Actinomycetales Infections: 1
        Mycobacterium Infections: 93
        Tuberculosis: 48666
        Multidrug-Resistant Tuberculosis: 2430
        Extensively Drug-Resistant Tuberculosis: 712

Pascaline Ravolonandriana Selected Research

Pascaline Ravolonandriana Research Topics

Disease

Drug/Important Bio-Agent (IBA)